UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 1, 2006
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-32085 | 36-4392754 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL 60654 |
||||
Registrant’s telephone number, including area code 1-800-654-0889.
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On August 1, the registrant announced its earnings for the three and six months ended June 30, 2006. Further details are described in the press release issued by the registrant on August 1, 2006, and furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Financial Measures
Allscripts reports its financial results in accordance with generally accepted accounting principles (“GAAP”). In addition, the Company reports on non-GAAP financial measures, such as cash earnings and cash earnings per share. Management believes that these non-GAAP measures, when viewed in addition to the Company’s reported GAAP results, provide useful information to investors regarding its performance and overall results of operations. Reconciliations to comparable GAAP measures are included as part of this release.
Item 9.01. Financial Statements and Exhibits.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press release issued August 1, 2006 | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. | ||||
| Date: August 1, 2006 |
By: |
/s/ William J. Davis | ||
| William J. Davis | ||||
| Chief Financial Officer | ||||
INDEX TO EXHIBITS
| Exhibit Number |
Description | |
| 99.1 | Press release issued August 1, 2006 |
Exhibit 99.1
| Allscripts Contacts: Dan Michelson Chief Marketing Officer 312-506-1217 dan.michelson@allscripts.com |
Bill Davis Chief Financial Officer 312-506-1211 bill.davis@allscripts.com |
FOR IMMEDIATE RELEASE
Allscripts Reports Record Results
Software and Related Services Revenue Increases 190% Over Prior Year
CHICAGO, IL – August 1, 2006 – Allscripts (Nasdaq: MDRX), the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare, today announced its results for the three and six months ended June 30, 2006.
Total revenue for the three months ended June 30, 2006 was $60.0 million, compared to $29.5 million for the same period last year. Revenue from software and related services for the three months ended June 30, 2006 was a record $46.7 million, compared to $16.1 million for the same period last year, increasing by approximately 190%. Revenue from software and related services reflects the first full quarter of integration with A4 Health Systems.
Gross margin percentage was approximately 52% for the second quarter of 2006, compared to 47% during the second quarter of 2005.
Net income for the three months ended June 30, 2006 was $2.8 million, or $0.05 per diluted share, compared to net income of $2.0 million, or $0.05 per diluted share, for the same period last year. Cash earnings for the three months ended June 30, 2006 was $9.8 million, or $0.18 per diluted share, compared to cash earnings of $3.6 million, or $0.08 per diluted share, for the same period last year. Cash earnings are comprised of net income giving effect to the add-back of income taxes, depreciation and amortization, stock-based compensation and one-time A4 integration costs. Please see “Financial Measures” below for a discussion of cash earnings and cash earnings per share.
As of June 30, 2006 the Company had cash and marketable securities of $65.8 million.
“The second quarter was the strongest in Allscripts history, with record earnings and strong sales growth, confirming that we continue to gain traction in the market by offering the right solutions at the right time,” commented Glen Tullman, Chief Executive Officer of Allscripts. “A4 contributed solid results in the first full quarter since the acquisition, confirming Allscripts as the clear leader across all segments of the ambulatory market, and demonstrating our ability to grow quickly while also investing in the future.”
Total revenue for the six months ended June 30, 2006 was $102.2 million, compared to $55.7 million for the six months ended June 30, 2005. Revenue from software and related services for the six months ended June 30, 2006 was $75.1 million, compared to $30.5 million for the same period last year, increasing by approximately 146%. Total revenue for the six months ended June 30, 2006 includes the results of A4 Health Systems, Inc. from the acquisition date of March 2, 2006 through the end of the second quarter of 2006.
Gross margin percentage was approximately 50% for the six months ended June 30, 2006 compared to 47% for the six months ended June 30, 2005.
Net income for the six months ended June 30, 2006 was $4.2 million, or $0.08 per diluted share, compared to net income of $3.4 million, or $0.08 per diluted share, for the same period last year. Cash earnings for the six months ended June 30, 2006 was $16.2 million, or $0.31 per diluted share, compared to cash earnings of $6.5 million, or $0.15 per diluted share, for the same period last year.
Financial Measures
Allscripts reports its financial results in accordance with generally accepted accounting principles (“GAAP”). In addition, the Company reports on non-GAAP financial measures, such as cash earnings and cash earnings per share. Management believes that these non-GAAP measures, when viewed in addition to the Company’s reported GAAP results, provide useful information to investors regarding its performance and overall results of operations. Reconciliations to comparable GAAP measures are included as part of this release.
Conference Call
Allscripts will conduct a conference call on Tuesday, August 1, 2006 at 4:30 PM eastern time. The conference call can be accessed by dialing 1-888-644-5594, or via the Internet at www.allscripts.com. A recording of the conference call will be available for review for a period of two weeks at www.allscripts.com or by calling 1-800-642-1687, ID # 3303435.
About Allscripts
Allscripts is the leading provider of clinical software, connectivity and information solutions that physicians use to improve healthcare. The Company’s business groups provide unique solutions that inform, connect and transform healthcare. The Clinical Solutions Group’s award-winning software applications include electronic health record, practice management, electronic prescribing, document imaging, emergency department and care management solutions. Additionally, Allscripts provides clinical product education and connectivity solutions for physicians and patients through its Physicians Interactive™ Group and medication fulfillment services through its Medication Services Group. To learn more, visit Allscripts at www.allscripts.com.
This announcement may contain forward-looking statements about Allscripts Healthcare Solutions that involve risks and uncertainties. These statements are developed by combining currently available information with Allscripts beliefs and assumptions. Forward-looking statements do not guarantee future performance. Because Allscripts cannot predict all of the risks and uncertainties that may affect it, or control the ones it does predict, Allscripts’ actual results may be materially different from the results expressed in its forward-looking statements. For a more complete discussion of the risks, uncertainties and assumptions that may affect Allscripts, see the Company’s 2005 Annual Report on Form 10-K, available through the Web site maintained by the Securities and Exchange Commission at www.sec.gov.
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(amounts in thousands)
(Unaudited)
| Assets | June 30, 2006 |
December 31, 2005 | ||
| Current assets: |
||||
| Cash and cash equivalents |
$32,978 | $60,905 | ||
| Marketable securities |
14,212 | 54,408 | ||
| Accounts receivable, net |
44,610 | 29,244 | ||
| Other receivables |
150 | 502 | ||
| Deferred taxes, net |
5,467 | — | ||
| Inventories |
5,124 | 2,174 | ||
| Prepaid expenses and other current assets |
6,800 | 5,811 | ||
| Total current assets |
109,341 | 153,044 | ||
| Long-term marketable securities |
18,626 | 30,750 | ||
| Fixed assets, net |
12,821 | 2,753 | ||
| Software development costs, net |
8,176 | 6,409 | ||
| Deferred taxes, net |
28,305 | — | ||
| Intangible assets, net |
83,641 | 9,151 | ||
| Goodwill |
182,801 | 13,760 | ||
| Other assets |
5,356 | 5,097 | ||
| Total assets |
$449,067 | $220,964 | ||
| Liabilities and Stockholders’ Equity | ||||
| Current liabilities: |
||||
| Accounts payable |
$10,434 | $8,630 | ||
| Accrued liabilities |
22,834 | 13,791 | ||
| Deferred revenue |
32,967 | 17,306 | ||
| Current portion of long-term debt |
248 | — | ||
| Total current liabilities |
66,483 | 39,727 | ||
| Long-term debt |
85,573 | 82,500 | ||
| Other liabilities |
313 | 318 | ||
| Total liabilities |
152,369 | 122,545 | ||
| Stockholders’ equity |
296,698 | 98,419 | ||
| Total liabilities and stockholders’ equity |
$449,067 | $220,964 | ||
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Operations
(amounts in thousands, except per-share amounts)
(Unaudited)
| Three Months Ended June 30, |
Six Months Ended June 30, |
|||||||||||||||
| 2006 | 2005 | 2006 | 2005 | |||||||||||||
| Revenue: |
||||||||||||||||
| Software and related services |
$ | 46,745 | $ | 16,145 | $ | 75,059 | $ | 30,455 | ||||||||
| Prepackaged medications |
10,508 | 11,489 | 22,018 | 21,324 | ||||||||||||
| Information services |
2,761 | 1,900 | 5,141 | 3,950 | ||||||||||||
| Total revenue |
60,014 | 29,534 | 102,218 | 55,729 | ||||||||||||
| Cost of revenue: |
||||||||||||||||
| Software and related services |
18,504 | 5,231 | 29,985 | 10,485 | ||||||||||||
| Prepackaged medications |
8,716 | 9,697 | 18,042 | 17,420 | ||||||||||||
| Information services |
1,522 | 725 | 2,794 | 1,776 | ||||||||||||
| Total cost of revenue |
28,742 | 15,653 | 50,821 | 29,681 | ||||||||||||
| Gross profit |
31,272 | 13,881 | 51,397 | 26,048 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Selling, general and administrative expenses |
22,706 | 11,458 | 39,107 | 21,815 | ||||||||||||
| Stock-based compensation expense |
416 | — | 823 | — | ||||||||||||
| Amortization of intangibles |
3,281 | 436 | 4,651 | 872 | ||||||||||||
| Income from operations |
4,869 | 1,987 | 6,816 | 3,361 | ||||||||||||
| Interest expense |
(940 | ) | (881 | ) | (1,835 | ) | (1,758 | ) | ||||||||
| Interest income |
639 | 957 | 1,838 | 1,834 | ||||||||||||
| Other expense, net |
(8 | ) | (30 | ) | (126 | ) | (70 | ) | ||||||||
| Income before income taxes |
4,560 | 2,033 | 6,693 | 3,367 | ||||||||||||
| Income taxes |
1,733 | — | 2,543 | — | ||||||||||||
| Net income |
$ | 2,827 | $ | 2,033 | $ | 4,150 | $ | 3,367 | ||||||||
| Net income per share—basic |
$ | 0.05 | $ | 0.05 | $ | 0.09 | $ | 0.09 | ||||||||
| Net income per share—diluted |
$ | 0.05 | $ | 0.05 | $ | 0.08 | $ | 0.08 | ||||||||
| Weighted average shares of common stock outstanding |
||||||||||||||||
| used in computing basic net income per share |
52,202 | 39,824 | 48,573 | 39,451 | ||||||||||||
| Weighted average shares of common stock outstanding |
||||||||||||||||
| used in computing diluted net income per share |
55,282 | 43,144 | 51,665 | 42,585 | ||||||||||||
Allscripts Healthcare Solutions, Inc.
Reconciliation of Non-GAAP Measure of Cash Earnings and Cash Earnings Per Share
(amounts in thousands, except per-share amounts)
(Unaudited)
| Three Months Ended June 30, |
Six Months Ended June 30, | |||||||||||
| 2006 | 2005 | 2006 | 2005 | |||||||||
| Net income, as reported |
$ | 2,827 | $ | 2,033 | $ | 4,150 | $ | 3,367 | ||||
| Add back: |
||||||||||||
| Income taxes |
1,733 | — | 2,543 | — | ||||||||
| Depreciation and amortization |
4,803 | 1,556 | 7,537 | 3,125 | ||||||||
| Stock-based compensation |
416 | — | 823 | — | ||||||||
| Realized losses on marketable securities (Note 1) |
— | — | 118 | — | ||||||||
| A4 Health Systems integration costs |
— | — | 1,021 | — | ||||||||
| Cash earnings |
$ | 9,779 | $ | 3,589 | $ | 16,192 | $ | 6,492 | ||||
| Cash earnings per share—basic |
$ | 0.19 | $ | 0.09 | $ | 0.33 | $ | 0.16 | ||||
| Cash earnings per share—diluted |
$ | 0.18 | $ | 0.08 | $ | 0.31 | $ | 0.15 | ||||
| Weighted average shares of common stock outstanding used in computing basic cash earnings per share |
52,202 | 39,824 | 48,573 | 39,451 | ||||||||
| Weighted average shares of common stock outstanding used in computing diluted cash earnings per share |
55,282 | 43,144 | 51,665 | 42,585 | ||||||||
Note 1 — Realized losses incurred as a result of the early maturity of marketable securities due to cash requirements related to the acquisition of A4 Health Systems, Inc.